3) Nakagawara J, Minematsu K, Okada Y, et al: Thrombolysis with 0.6mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41: 1984-1989.
4) Toyoda K, Koga M, Naganuma M, et al: Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 2009; 40: 3591-3595.
5) Whiteley WN, Slot KB, Fernandes P, et al: Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis of 55 studies. Stroke 2012; 43: 2904-2909.